RNS Number:7319M
Robotic Technology Systems PLC
25 June 2003



                         Robotic Technology Systems PLC
                            ("RTS" or the "Company")

                               AGM Trading Update


At the AGM of RTS, to be held later today, the Company will make the following
statement on current trading and its view of market conditions as it approaches
the end of the first half.

We are pleased to report that order intake in our largest US-based business has
improved as the year has progressed.  Order input in the US in the second
quarter of the current year will be higher than the comparative quarter in 2002
and is already the second highest quarterly intake since the third quarter of
2001, with good wins in the Assembly Systems, Build-to-Print and Tooling Systems
business groups. Its order backlog at the end of the current quarter will
therefore be some #4 million higher than at the end of the first quarter. Whilst
customers are still cautious, confidence in the US industrial market appears to
be slowly improving and we are starting to see opportunities of a higher value
than for some months. The lower breakeven point of our US operations, resulting
from the decisive and substantial cost reduction programme executed over the
past year, is now within reach at these order input levels and should enable a
substantial turnaround from the large losses incurred in 2002.

We are also pleased to report continuing progress in the UK-led businesses in
Life Science and Nuclear Solutions which both had record performances in 2002.

Life Science, the Group's highest margin business, booked orders in the first
half of 2003 in line with forecast and its current order backlog stands at #13
million.  A large Swiss pharmaceutical company has been added to the impressive
list of global customers with two orders being received in the first half.  RTS
Life Science recently entered into a partnership with Syrrx Inc, a drug
discovery company based in California which is directing its efforts towards
developing therapeutics to treat cancer, metabolic diseases and inflammation, to
develop and market an automated high throughput system for use in structural
biology applications.  The product, which will be known as the HTSB FactoryTM,
will aim to enhance greatly the performance of chemists in this area of drug
discovery.  Syrrx, has partnered with RTS Life Science to develop the next
generation of automation for protein crystallography because of RTS' experience
in providing automated solutions for compound management, cell culture and high
throughput screening to the pharmaceutical industry.  In the past, protein
crystallography process that will be used was repetitive, slow and hampered by
lack of automation.  Having transformed high throughput screening automation
over the last four years, RTS believes that this partnership could do the same
in this field.

Nuclear Solutions business in the UK continues to progress.  A long term and
prestigious contract to provide design services to BNFL for the B38 Hazard
Reduction Project at Sellafield has been awarded to an alliance headed by RTS
Nuclear Solutions.  This represents a significant advance for our Nuclear
Solutions Business Group as design solutions had previously been provided by the
Alliance members and others on a piecemeal basis.  The Nuclear Solutions
business unit based in the US has recently won its first significant order at
the Hanford nuclear site and is busily quoting on a range of other opportunities
at Hanford and other sites including Savannah River, where RTS is well
established, which are anticipated to be let over the next few months.

We are pleased to report that our UK-based Flexible Systems business, which
specialises in advanced robotic applications, is making significant progress in
its target market which is technology based packaging and product handling
applications for the food industry. First orders have been won during the year
from two major UK companies including one for #750,000 from a national bakery
group for intelligent bread tin handling. The Group's proprietary software
technology, which is embedded in our Vision Integration Platform VIPTM and
FlexMillTM products, is now firmly established in the UK following its
successful transfer from the Group's Finnish operations which were sold in late
2002.

In summary, the UK-based businesses in Life Science and Nuclear Solutions
continue to perform strongly and Flexible Systems is progressing in line with
expectations. More importantly, the trading conditions for our US-based
businesses have shown some signs of improvement over recent months and the cost
savings anticipated from the rationalisation programme in our US operations of
some #8 million annualised are on track.  However, whilst we are pleased with
the progress that has been made so far this year, we will continue to be
extremely cautious in our view of the market place, especially so in the US,
until there is more evidence of a sustained improvement.  We will continue
therefore to maintain tight cash and cost controls throughout the group.


                                                                    25 June 2003

Enquiries:

Robotic Technology Systems PLC                                     0161 777 2000
Phil Johnson, Chief Executive Officer
David Timmins, Group Finance Director

College Hill
Matthew Smallwood                                                  020 7457 2020



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
AGMILFIDRDISFIV